9EN.F PHARVARIS N.V. EO -12

Healthcare Biotechnology Frankfurt Exchange
30.70 EUR
Close of Nov 11, 2026
19.70 38.25
Market cap
EUR 2.16B
P/E
-
P/B
7.02x
ROE
-57.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 9EN.F undervalued?

Graham number

The Graham number of PHARVARIS N.V. EO -12 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

PHARVARIS N.V. EO -12 fundamental analysis

No fundamental analysis for PHARVARIS N.V. EO -12 yet.

PHARVARIS N.V. EO -12 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About PHARVARIS N.V. EO -12

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase…

Full company profile